Form 8-K - Current report:
SEC Accession No. 0001193125-21-314472
Filing Date
2021-11-01
Accepted
2021-11-01 07:32:37
Documents
12
Period of Report
2021-11-01
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure

Document Format Files

Seq Description Document Type Size
1 8-K d52219d8k.htm   iXBRL 8-K 24062
  Complete submission text file 0001193125-21-314472.txt   142006

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA mrtx-20211101.xsd EX-101.SCH 2874
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE mrtx-20211101_lab.xml EX-101.LAB 17374
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mrtx-20211101_pre.xml EX-101.PRE 10941
5 EXTRACTED XBRL INSTANCE DOCUMENT d52219d8k_htm.xml XML 3205
Mailing Address 3545 CRAY COURT SAN DIEGO CA 92121
Business Address 3545 CRAY COURT SAN DIEGO CA 92121 858-332-3410
Mirati Therapeutics, Inc. (Filer) CIK: 0001576263 (see all company filings)

EIN.: 462693615 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35921 | Film No.: 211365310
SIC: 2834 Pharmaceutical Preparations